Will current clinical trials answer the most important questions about prostate adenocarcinoma?
Despite a heightened focus of the medical and research community on prostate cancer, many important questions about this disease remain unanswered. These include questions about the possible prevention of prostate cancer, as well as the optimal treatment approaches for localized, locally advanced, metastatic, and hormone-refractory disease. A whole host of prospective, well-designed clinical trials are currently in progress that should answer many of these questions. This review briefly explores some of these unresolved issues and describes ongoing trials designed to address them.
Thompson
I M
IM
Department of Surgery, Brooke Army Medical Center, San Antonio, Texas, USA.
Seay
T M
TM
D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control / Q000556:secondary / Q000628:therapy*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D005060:Europe; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D014481:United States